Polypharmacy and sarcopenia in hospitalized older patients: results of the GLISTEN study.
In-patients
Polypharmacy
Sarcopenia
Skeletal muscle
Journal
Aging clinical and experimental research
ISSN: 1720-8319
Titre abrégé: Aging Clin Exp Res
Pays: Germany
ID NLM: 101132995
Informations de publication
Date de publication:
Apr 2019
Apr 2019
Historique:
received:
06
07
2018
accepted:
18
01
2019
pubmed:
20
2
2019
medline:
9
5
2019
entrez:
20
2
2019
Statut:
ppublish
Résumé
Recently the Berlin Aging Study II (BASE-II) showed that polypharmacy is associated with clinically relevant sarcopenia among community-dwelling older persons. Here we report findings from the GLISTEN study about the association of polypharmacy with sarcopenia among older medical in-patients. The GLISTEN study investigated prevalence and clinical correlates of sarcopenia in older patients admitted to geriatric and internal medicine acute care wards of 12 Italian hospitals. In this sample of older medical in-patients with high prevalence of sarcopenia (34.7%) and polypharmacy (70.2%) we did not observe a significant association of polypharmacy with sarcopenia. Present findings demonstrate that the association of polypharmacy with sarcopenia, observed in the BASE-II study, is not evident in the GLISTEN sample, being our patients significantly older, more multi-morbid, with high prevalence of sarcopenia and polypharmacy, suggesting that this association might vary according to the heterogeneous health, functional, and nutritional characteristics of older people.
Sections du résumé
BACKGROUND
BACKGROUND
Recently the Berlin Aging Study II (BASE-II) showed that polypharmacy is associated with clinically relevant sarcopenia among community-dwelling older persons. Here we report findings from the GLISTEN study about the association of polypharmacy with sarcopenia among older medical in-patients.
METHODS
METHODS
The GLISTEN study investigated prevalence and clinical correlates of sarcopenia in older patients admitted to geriatric and internal medicine acute care wards of 12 Italian hospitals.
RESULTS
RESULTS
In this sample of older medical in-patients with high prevalence of sarcopenia (34.7%) and polypharmacy (70.2%) we did not observe a significant association of polypharmacy with sarcopenia.
CONCLUSIONS
CONCLUSIONS
Present findings demonstrate that the association of polypharmacy with sarcopenia, observed in the BASE-II study, is not evident in the GLISTEN sample, being our patients significantly older, more multi-morbid, with high prevalence of sarcopenia and polypharmacy, suggesting that this association might vary according to the heterogeneous health, functional, and nutritional characteristics of older people.
Identifiants
pubmed: 30778874
doi: 10.1007/s40520-019-01136-3
pii: 10.1007/s40520-019-01136-3
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
557-559Investigateurs
Gloria Brombo
(G)
Beatrice Ortolani
(B)
Elisabetta Savino
(E)
Elisa Maietti
(E)
Alberto Fisichella
(A)
Valeria Buttò
(V)
Mauro Zamboni
(M)
Cesare Caliari
(C)
Elena Ferrari
(E)
Francesco Orso
(F)
Flavia Sacco
(F)
Laura Di Meo
(L)
Anna Paola Cerri
(AP)
Marco Motta
(M)
Francesca Pittella
(F)
Alessandra Bonfanti
(A)
Sergio Fusco
(S)
Valeria Prestipino Giarritta
(V)
Luca Soraci
(L)
Fausto Giordano Pili
(FG)
Claudia Basile
(C)
Carla Coppola
(C)
Anna Maria Dalise
(AM)
Ilaria Fava
(I)
Olga Catte
(O)
Maura Orrù
(M)
Paolo Salaris
(P)
Anna Maria Martone
(AM)
Elena Ortolani
(E)
Sara Salini
(S)
Giuseppina dell'Aquila
(G)
Barbara Carrier
(B)